Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood, and capillary blood taken simultaneously from 24 healthy volunteers. Median (range) venous-blood-to-plasma ratios were 1.42 (0.920 to 1.97) for oseltamivir and 0.673 (0.564 to 0.814) for oseltamivir carboxylate. Capillary blood/venous plasma ratios were 1.32 (0.737 to 3.16) for oseltamivir and 0.685 (0.502 to 1.34) for oseltamivir carboxylate. Oseltamivir concentrations in venous and capillary blood were similar. Oseltamivir carboxylate showed a time-dependent distribution between venous and capillary blood
<p>Panel A shows the pharmacokinetics for twice-a-day intake for 5 days and the panel B once a day i...
Kyungho Jang,1,2,* Min-Kyoung Kim,3,4,* Jaeseong Oh,1 SeungHwan Lee,1 Joo-Youn Cho,1 Kyung-Sang Yu,1...
<p>Area under the concentration versus time curve (AUC<sub>0t</sub>) is indicated. Values represent ...
The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four...
The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxyla...
AbstractA simple, precise and rapid liquid chromatography–tandem mass spectrometry (LC–MS/MS) method...
<p>For clarity, the OC concentrations from the exit limb (e) to the effluent bags are shown for Pati...
Introduction: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) support on pharma...
A bioanalytical method for the analysis of oseltamivir (OP) and its metabolite oseltamivir carboxyla...
There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used ...
There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used ...
textabstractThe neuraminidase inhibitor oseltamivir (Tamiflu®) is currently the first-line therapy f...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/94511/1/phar1151.pd
<p>Plasma concentrations (µg/l) are depicted for each individual patient in time (h). Individual pat...
Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the inf...
<p>Panel A shows the pharmacokinetics for twice-a-day intake for 5 days and the panel B once a day i...
Kyungho Jang,1,2,* Min-Kyoung Kim,3,4,* Jaeseong Oh,1 SeungHwan Lee,1 Joo-Youn Cho,1 Kyung-Sang Yu,1...
<p>Area under the concentration versus time curve (AUC<sub>0t</sub>) is indicated. Values represent ...
The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four...
The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxyla...
AbstractA simple, precise and rapid liquid chromatography–tandem mass spectrometry (LC–MS/MS) method...
<p>For clarity, the OC concentrations from the exit limb (e) to the effluent bags are shown for Pati...
Introduction: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) support on pharma...
A bioanalytical method for the analysis of oseltamivir (OP) and its metabolite oseltamivir carboxyla...
There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used ...
There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used ...
textabstractThe neuraminidase inhibitor oseltamivir (Tamiflu®) is currently the first-line therapy f...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/94511/1/phar1151.pd
<p>Plasma concentrations (µg/l) are depicted for each individual patient in time (h). Individual pat...
Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the inf...
<p>Panel A shows the pharmacokinetics for twice-a-day intake for 5 days and the panel B once a day i...
Kyungho Jang,1,2,* Min-Kyoung Kim,3,4,* Jaeseong Oh,1 SeungHwan Lee,1 Joo-Youn Cho,1 Kyung-Sang Yu,1...
<p>Area under the concentration versus time curve (AUC<sub>0t</sub>) is indicated. Values represent ...